Ionizable Cationic Lipid Nanoparticles for Stable RNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for stable and effective lipid formulations that can easily deliver biologically active molecules, such as nucleic acids, to target tissues and cells, as existing methods face challenges in reaching these sites effectively.
Innovation Solution
Development of novel lipid compositions, including compounds of Formula 1, which form nanoparticles or bilayers with neutral lipids and polymers, encapsulating nucleic acids to facilitate targeted intracellular delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleic acids are delivered using conventional methods, then delivery to target cells is attempted, but the ability to reach targeted cells and tissues is limited
Solution Approach 1:
The patent employs composite lipid formulations comprising multiple lipid components with specific structural features (Formula 1 lipids combined with helper lipids like cholesterol and PEG-lipids). These composite materials create nanoparticles that effectively deliver nucleic acids to target cells while maintaining manageable formulation complexity through standardized compositional ratios and preparation methods.
2Reliability
If lipid formulations are developed to deliver nucleic acids effectively, then delivery capability improves, but formulation stability and shelf-life become challenging
Solution Approach 1:
The patent optimizes specific parameters of the lipid molecules including chain length, saturation, and head group composition to achieve the desired balance between delivery effectiveness and formulation stability. The Formula 1 lipids are designed with specific structural parameters that enable stable nanoparticle formation while maintaining delivery capability.
Solution Approach 2:
The use of composite lipid formulations with multiple components (Formula 1 lipids, helper lipids, PEG-lipids) creates synergistic effects that simultaneously improve delivery capability and formulation stability. The different lipid components work together to stabilize the nanoparticle structure while maintaining nucleic acid delivery effectiveness.
3Reliability
If nucleic acids are encapsulated in lipid formulations, then intracellular delivery is facilitated, but the formulation must be easy to manufacture
Solution Approach 1:
The lipid components are pre-synthesized and characterized before formulation, with the Formula 1 lipids being prepared in advance with specific structural features. This preliminary preparation of standardized lipid components simplifies the final formulation process and enables scalable manufacturing while maintaining intracellular delivery effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel lipid compositions enhance the delivery of nucleic acids to cells, particularly in tissues like liver, lung, kidney, brain, and blood, offering therapeutic benefits for conditions like cancer and inflammation.
Implementation Method 1
the compounds described herein may be combined with other cationic lipid compounds, polymers (synthetic or natural), surfactants, cholesterol, carbohydrates, proteins, lipids, etc. to form the particles
Implementation Method 2
The compounds of formula (1) form salts that are also within the scope of this disclosure. Also within the scope of this disclosure are polymorphs of the compounds of formula (1)
Data Source
AI summary
What is described is a compound of formula (1)whereinR1 and R2 are the same or different, each a linear or branched alkyl with 1-9 carbons, or an alkenyl or alkynyl with 2 to 11 carbon atoms;L1 and L2 are the same or different, each a linear alkyl having 5 to 18 carbon atoms, or form a heterocycle with N;X1 is a bond, or is —CO—O— whereby L2-CO—O—R2 is formed;X2 is S or O; L3 is a bond or a lower alkyl, or form a heterocycle with N;R3 is a lower alkyl; and R4 and R5 are the same or different, each a lower alkyl;or a pharmaceutically acceptable salt thereof.